{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"From MSCs to iPSCs: building the cell therapy future","slug":"from-mscs-to-ipscs-building-the-cell-therapy-future","published_at":"2026-05-14T07:00:00+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/from-mscs-to-ipscs-building-the-cell-therapy-future","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/e3f666d25e76c7da4d3d0f0c9b9a3216ca9874f751649aba41dcced8868191e7/eyJlcGlzb2RlSWQiOiI5ZGIzNGY2NC1iMTZiLTQwYWQtYjRmZi01NjJmZTUzZDNiZjMiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEwNGExZGFiMGUyMGEyMDQ0ZGE4YWMwL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi01LTEzX18xOC03LTU0Lm1wMyJ9.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/e3f666d25e76c7da4d3d0f0c9b9a3216ca9874f751649aba41dcced8868191e7/eyJlcGlzb2RlSWQiOiI5ZGIzNGY2NC1iMTZiLTQwYWQtYjRmZi01NjJmZTUzZDNiZjMiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEwNGExZGFiMGUyMGEyMDQ0ZGE4YWMwL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi01LTEzX18xOC03LTU0Lm1wMyJ9.mp3","summary":"In this episode of Denatured, you'll be hearing from Miguel Forte, president of the International Society for Cell and Gene Therapy (ISCT), and John Ellis, co-founder & CEO of Trenchant Bios, speaking live from the ISCT annual meeting. We dive into mesenchymal stem cells and induced pluripotent stem cells, exploring the science behind them, the manufacturing challenges, and the potential for scalable, engineered next-generation therapies. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Jon Ellis , Co-founder & CEO, Trenchant Bio Miguel Forte , President, International Society for Cell & Gene Therapy Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.","meta_description":"In this episode of Denatured, you'll be hearing from Miguel Forte, president of the International Society for Cell and Gene Therapy (ISCT), and John Ellis…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1225,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/from-mscs-to-ipscs-building-the-cell-therapy-future/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/from-mscs-to-ipscs-building-the-cell-therapy-future.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}